/

PHIO

Phio Pharmaceuticals Corp.Closed

0.9345+0.01 +1.36%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.9400 +0.59%

Open

0.9600

Prev close

0.9220

Day range

0.92010.9600

52-week range

0.81304.19

Volume

69.18K0.12×

Mkt cap

10.86M

P/E ttm

—

Fwd P/E

-1.53

EPS ttm

-1.29

Div yield

0.00%

Earnings

—

From 52w high

−77.70%

Price Chart

Yahoo Finance · delayed

PHIOOct 13, 2026O 0.9600H 0.9600L 0.9200C 0.9350+0.0130 (+1.41%)Vol 69.20K

SMA 501.0544
SMA 2001.1037

1Y change −57.54% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PHIO Phio Pharmaceuticals Corp. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.94%
1 month: −9.22%
3 months: −9.22%
6 months: −27.52%
Year to date: −10.95%
1 year: −57.11%

Valuation & ownership

Market cap: 10.86M
Enterprise value: −2.14M
P/E (ttm): —
Forward P/E: -1.53
PEG ratio: —
Price / book: 0.86
Price / sales (ttm): —
EV / EBITDA: 0.16
EPS (ttm): -1.29
EPS (forward): -0.6100
Beta (5y monthly): 0.84
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 11.62M
Float: 11.26M
Short % of float: 0.77%
Short ratio (days): 0.64
Held by insiders: 8.01%
Held by institutions: 10.21%
Avg volume (3m): 588.51K
50-day average: 1.06
200-day average: 1.10
52-week change: −57.11%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 34.2
vs 50-day SMA: −11.32%
vs 200-day SMA: −15.28%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.72%
Realised vol (20d, ann.): 32.0%
From 52-week high: −77.68%
From 52-week low: +15.01%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

14.00

+1,398.13% implied

Low 14.00Median 14.00High 14.00

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0
2m ago

DES

About Phio Pharmaceuticals Corp.

Yahoo Finance profile

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 6
Headquarters: King of Prussia, PA, United States
Website: phiopharma.com
Officers: Mr. Robert J. Bitterman President, CEO & Chairman
Ms. Lisa C. Carson CFO, Principal Accounting Officer and VP of Finance & Administration
Ms. Linda M. Mahoney Senior Vice President of Development
Dr. Jennifer Phillips Pharm.D. Senior Vice President of Regulatory & Corporate Affairs

SEAS

Seasonality · PHIO

2012–2026 · monthly returns

Strongest month Feb +5.31%Weakest month Dec −13.87%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.8	12.9	7.0	0.0	-9.0	-7.7	0.0	6.3	-5.5	-9.3			−11.0%
2025	14.4	-31.1	-8.5	47.7	4.2	17.5	1.3	-17.2	25.9	-17.3	-38.5	-16.7	−41.7%
2024	-21.8	81.8	-37.0	2.2	5.0	-5.2	-48.6	-15.0	26.8	-13.6	-8.7	-33.8	−73.7%
2023	39.4	-11.9	2.6	-39.9	3.6	-18.0	-7.0	-20.2	-29.1	-17.9	-11.8	-30.5	−83.0%
2022	-12.5	-7.4	9.5	-5.3	-13.7	-3.2	1.9	-2.1	-18.4	0.7	-27.0	-11.4	−62.8%
2021	16.4	-8.6	-6.3	-13.8	-3.9	1.8	-20.4	15.6	-2.4	-17.2	-19.6	-25.9	−62.8%
2020	-2.1	-68.2	-39.6	7.9	59.7	-28.2	13.2	-6.9	-7.4	-2.8	12.5	15.0	−71.4%
2019	10.6	4.1	18.4	8.9	-12.2	-11.6	2.6	-16.9	-15.1	-18.2	-36.4	19.6	−48.2%
2018	-25.2	-32.7	15.0	-21.7	-4.4	-19.9	-23.3	4.7	-24.5	-62.8	-24.1	0.0	−94.1%
2017	-11.9	7.9	19.1	-20.2	-14.6	6.2	4.1	-6.6	-15.8	13.5	14.9	-11.2	−22.2%
2016	-23.3	-4.4	-3.6	-17.8	-0.5	8.6	-2.1	-3.3	-18.6	-37.3	30.2	-52.6	−81.3%
2015	-31.9	6.4	-37.9	-9.6	-44.1	34.6	-16.3	-2.2	-7.5	11.9	2.2	-9.9	−76.1%
2014	60.3	29.2	-29.0	-23.9	-17.2	12.3	-17.5	19.7	-32.9	-0.5	-1.5	-18.4	−44.8%
2013	4.0	103.8	79.2	-26.3	-4.8	-3.5	-28.0	-18.5	2.9	-12.9	1.6	-6.5	+28.9%
2012						62.5	-7.7	1.7	-13.1	-10.4	-10.5	-11.8	−6.3%

INSD

Insider Activity · PHIO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 28, 2026	Plott Ronald ToddDirector	Purchase at price 1.03 - 1.04 per share.	10K	$10.35K
Sep 27, 2026	Bitterman Robert JChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	400K	—
Sep 27, 2026	Plott Ronald ToddDirector	Stock Award(Grant) at price 0.00 per share.	17K	—
Sep 27, 2026	Carson Lisa CabottChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	108K	—
Sep 21, 2026	Bitterman Robert JChief Executive Officer	Purchase at price 1.03 per share.	2K	$2.06K
Sep 14, 2026	Bradford Patricia ADirector	Purchase at price 1.03 per share.	12K	$12.36K
Aug 18, 2026	Plott Ronald ToddDirector	Purchase at price 1.14 per share.	15K	$17.10K
Aug 17, 2026	Bitterman Robert JChief Executive Officer	Purchase at price 1.06 per share.	10K	$10.60K
Jun 25, 2026	Bitterman Robert JChief Executive Officer	Purchase at price 0.99 per share.	10K	$9.90K
Feb 4, 2026	Bitterman Robert JChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	120K	—
Feb 4, 2026	Bradford Patricia ADirector	Stock Award(Grant) at price 0.00 per share.	18.5K	—
Feb 4, 2026	Lockshin CurtisDirector	Stock Award(Grant) at price 0.00 per share.	16.6K	—
Feb 4, 2026	Deming David HDirector	Stock Award(Grant) at price 0.00 per share.	23.8K	—
Feb 4, 2026	Freeman Jonathan E Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	16.6K	—
Feb 4, 2026	Carson Lisa CabottChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	47K	—
Dec 30, 2025	Bitterman Robert JChief Executive Officer	Purchase at price 1.03 per share.	5K	$5.15K
Dec 22, 2025	Bitterman Robert JChief Executive Officer	Purchase at price 1.02 per share.	5K	$5.10K
Nov 20, 2025	Bitterman Robert JChief Executive Officer	Purchase at price 1.14 per share.	5K	$5.70K
Nov 17, 2025	Bitterman Robert JChief Executive Officer	Purchase at price 1.27 per share.	5K	$6.35K
Sep 10, 2025	Bitterman Robert JChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	250K	—

PHIO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PHIO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Phio Pharmaceuticals Corp.

Seasonality · PHIO

Insider Activity · PHIO

Congress Trades · PHIO

Investors Holding PHIO

Investors Holding PHIO

Congress Trades · PHIO

Insider Activity · PHIO

Seasonality · PHIO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Phio Pharmaceuticals Corp.

Financial Snapshot

Earnings & Dividends

News